Expert consensus on the clinical application of recombinant adenovirus human p53 for head and neck cancers

The first gene therapy product, recombinant adenovirus human p53 (rAd-p53), has been approved by CFDA since 2013. During these years, most of the clinical trials and the relevant basic research were carried out by Chinese oncologists. Gendicine was proved to be a safe and promising gene therapy drug...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Yi Li, Wei Guo, Xiuqin Li, Jianguo Zhang, Moyi Sun, Zhangui Tang, Wei Ran, Kai Yang, Guilin Huang, Longjiang Li
Formato: article
Lenguaje:EN
Publicado: Nature Publishing Group 2021
Materias:
Acceso en línea:https://doaj.org/article/d58a102c0f7349e89574158df0039104
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!